Table 2.
Microbe | Experimental model | Mushroom product | Antimicrobial effect/Mechanism | Author | References |
---|---|---|---|---|---|
Streptococcus pneumoniae serotype 6 | Mice, sepsis | Mycelium extract incl. HE, GF (Andosan) p.o. |
Reduced bacteraemia, Increased survival |
Bernardshaw et al, 2005 | [39] |
Streptococcus mutans | In vitro | Erinacine from HE | Suppressed mutacin synthesis | Premnath et al, 2018 | [43] |
Faecal Gram neg. bacteria | Mice, sepsis | Mycelium extract incl. HE, GF, (Andosan), p.o. |
Reduced bacteraemia, Increased survival |
Bernardshaw et al, 2006 | [40] |
Pseudomonas aeruginosa | In vitro | AbM | Antiquorum sensing | Sokovic et al, 2014 | [44] |
Pseudomonas sp, pathogen opportunists | Plaque formation inhib. test | GF furanone | Inhibition | He et al, 2016 | [48] |
Helicobacter pylori | In vitro | HE extract | Inhibition | Liu et al, 2016 | [49] |
In vitro & Mouse colonization assay | HE extract | Inhibition | Wang et al, 2019 | [51] | |
Microbiota | Mice | HE | Improved colonic health | Wang et al, 2018 | [52] |
Leishmania | Mice, visceral L | AbM extract | Th1 response | Valadares et al, 2012 | [45] |
Mice | AbM extract | Th1 response | de Jesus Pereira et al, 2015 | [46] | |
Plasmodium berghei | Mice, cerebral malaria | AbM | Improved outcome | Val et al, 2015 | [47] |